Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The Failure of Solanezumab — How the FDA Saved Taxpayers Billions

Sacks, Chana A., Avorn, Jerry, Kesselheim, Aaron S. · 2017 · New England Journal of Medicine

Abstract

The failure of solanezumab offers a window into the U.S. drug regulatory system, particularly in the context of the 21st Century Cures Act and the national debate about the role of the FDA. The solanezumab story is an important case of a regulatory system that worked.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmp1701047

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Cited by

See all 55

Metadata

Authors
Sacks, C. A., Avorn, J., & Kesselheim, A. S.
Affiliations
Brigham and Women's Hospital (US)
Venue
New England Journal of Medicine
Published
2017-05-04
Volume
376
Issue
18
Pages
1706-1708
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2611277309
Cited by
55
References
2
Citations by year
2026: 3 · 2024: 4 · 2023: 2 · 2022: 2 · 2021: 11 · 2020: 4 · 2019: 9 · 2018: 12 · 2017: 8
FWCI
6.68
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Regulation
Keywords
solanezumab, FDA oversight, 21st Century Cures Act, drug approval, drug development costs
MeSH terms
Alzheimer Disease, Dementia, Humans, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Drug Costs, Cost Savings, Treatment Failure, Drug Approval, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Failure of Solanezumab — How the FDA Saved Taxpayers Billions. https://app.cochat.ai/papers/10.1056/nejmp1701047
The paper
Sacks, C. A., Avorn, J., & Kesselheim, A. S. (2017). The Failure of Solanezumab — How the FDA Saved Taxpayers Billions. New England Journal of Medicine. https://doi.org/10.1056/nejmp1701047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.